drugset / Trial / NCT04056481

Expanded Access Protocol of Givosiran for Patients With Acute Hepatic Porphyria

NCT04056481 ↗

Expanded access Approved for marketing Alnylam Pharmaceuticals

Summary

The purpose of this study is to provide expanded access of givosiran to patients with Acute Hepatic Porphyria (AHP).

Timeline

Start
—
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Givosiran Small interfering RNA (siRNA) — Subcutaneous

Indications